Search Results - "Amin, Manik A."

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma by Grierson, Patrick M, Tan, Benjamin, Pedersen, Katrina S, Park, Haeseong, Suresh, Rama, Amin, Manik A, Trikalinos, Nikolaos A, Knoerzer, Deborah, Kreider, Brent, Reddy, Anupama, Liu, Jingxia, Der, Channing J, Wang-Gillam, Andrea, Lim, Kian-Huat

“…Ulixertinib is a novel oral ERK inhibitor that has shown promising single-agent activity in a phase I clinical trial that included patients with RAS-mutant…”
Get full text

Surveillance With Serial Imaging and CA 19-9 Tumor Marker Testing After Resection of Pancreatic Cancer: A Single-Center Retrospective Study by Nong, Minerva Z, Dove, Devanshi, Fischer, Dawn A, Hourdequin, Kathryn C, Ripple, Gregory H, Amin, Manik A, McGrath, Elizabeth B, Zaki, Bassem I, Smith, Kerrington D, Brooks, Gabriel A

“…Most patients receiving curative-intent surgery for pancreatic cancer will experience cancer recurrence. However, evidence that postoperative surveillance…”
Get full text

A simple method to combine multiple molecular biomarkers for dichotomous diagnostic classification by Mamtani, Manju R, Thakre, Tushar P, Kalkonde, Mrunal Y, Amin, Manik A, Kalkonde, Yogeshwar V, Amin, Amit P, Kulkarni, Hemant

“…In spite of the recognized diagnostic potential of biomarkers, the quest for squelching noise and wringing in information from a given set of biomarkers…”
Get full text

Platelet distribution width (PDW) is increased in vaso-occlusive crisis in sickle cell disease by Amin, Manik A, Amin, Amit P, Kulkarni, Hemant R

“…Considering the multigenic and multifactorial nature of the disease, we argue that a generalized bone marrow hyperplasia-and not merely erythroid…”
Get full text

Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) of gastrointestinal (GI) tract: A single institution experience by Amin, Manik A., Trikalinos, Nikolaos

“…Abstract only 633 Background: MiNENs are heterogeneous group of rare tumors and represent less than 1% of all GI malignancies. These are pathologically…”
Get full text

Temozolomide treatment duration and secondary hematological neoplasms: A review of the literature and implications for patients with neuroendocrine tumors by Park, Robin, Amin, Manik A., Trikalinos, Nikolaos A.

“…Abstract only 510 Background: Evidence-based recommendations for the optimal duration of temozolomide-based treatment in advanced neuroendocrine neoplasms are…”
Get full text

A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy by Grierson, Patrick, Suresh, Rama, Tan, Benjamin R., Pedersen, Katrina Sophia, Amin, Manik A., Park, Haeseong, Trikalinos, Nikolaos, Liu, Jingxia, Lim, Kian-Huat, wang-gillam, Andrea, Bansod, Sapana Prakashrao

“…e16263 Background: 5-FU-based chemotherapy is the standard of care for patients with advanced pancreatic cancer progressed on gemcitabine-based therapy. Based…”
Get full text

Enhancing appendiceal cancer care: Towards evidence-based practice and continuous education for healthcare providers by Wu, Sulin, Nimer, Jenna, Gujarathi, Rushabh, Bansal, Varun Vivek, Liao, Chih-Yi, Amin, Manik A., Chin, Janet, Moller, Mecker, Merkow, Ryan P, Eng, Oliver S., Polite, Blase N., Turaga, Kiran, Shergill, Ardaman

“…e16377 Background: Appendiceal cancers (AC) are a set of rare and histologically diverse malignancies with distinct biological features and treatment…”
Get full text

Association of plasma uracil concentration with 5-FU pharmacokinetics, dose-limiting toxicity, and DPYD genotype in patients with gastrointestinal cancer by Brooks, Gabriel A., Ness, Dylan B., Hourdequin, Kathryn Cunningham, Ripple, Gregory H., Amin, Manik A., Lord-Halvorson, Sierra, Khan, Wahab A., Deharvengt, Sophie J., Dragnev, Konstantin H., Tsongalis, Gregory J., Zhao, Wenyan, Tosteson, Tor D., Lewis, Lionel D

“…751 Background: Plasma uracil concentration >16 ng/mL is used in some countries as a screening test for DPD deficiency. We conducted this exploratory study to…”
Get full text

A pilot study of liposomal irinotecan plus 5-FU/ LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy by Grierson, Patrick, Suresh, Rama, Tan, Benjamin R., Pedersen, Katrina Sophia, Amin, Manik A., Park, Haeseong, Trikalinos, Nikolaos, Liu, Jingxia, Lim, Kian-Huat, wang-gillam, Andrea

“…Abstract only 566 Background: 5-FU-based chemotherapy is the standard of care for patients with advanced pancreatic cancer progressed on gemcitabine-based…”
Get full text

A pragmatic, single-arm clinical trial of a dose-adjustment algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy by Brooks, Gabriel A., Wright, Heather, Ripple, Gregory H., Amin, Manik A., Fuld, Alexander D., Muralikrishnan, Sivraj, McGrath, Elizabeth Boutin, Stannard, Maureen G., Schofield, Lora L., Lord-Halvorson, Sierra, Lachance, Grace R., Tosteson, Tor D., Tosteson, Anna N.A., Dragnev, Konstantin H., Hourdequin, Kathryn Cunningham

“…6608 Background: Unplanned delays are common during FOLFOX chemotherapy, and cytopenias (neutropenia and/or thrombocytopenia) are the most common cause of…”
Get full text

Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer by Brooks, Gabriel A., Waleed, Mohammad, McGrath, Elizabeth Boutin, Beloin, Kara, Walsh, Sarah K., Benoit, Philip R., Khan, Wahab A., Tsongalis, Gregory J., Amin, Manik A., Faris, Jason Edward, Ripple, Gregory H., Hourdequin, Kathryn Cunningham

“…Abstract only 216 Background: Dihyropyrimidine dehydrogenase (DPD) deficiency is present in 3-5% of patients, and is associated with substantially increased…”
Get full text

A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy by Grierson, Patrick, Wang-Gillam, Andrea, Park, Haeseong, Pedersen, Katrina, Tan, Benjamin R., Amin, Manik A., Suresh, Rama, Trikalinos, Nikolaos, Liu, Jingxia

“…Abstract only TPS793 Background: Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related death by 2030, and is…”
Get full text

Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208 by Spiliopoulou, Pavlina, Kasi, Anup, Abushahin, Laith I., Cardin, Dana Backlund, Lenz, Heinz-Josef, Dayyani, Farshid, Messersmith, Wells A., Ezenwajiaku, Nkiruka, Oberstein, Paul Eliezer, Paluri, Ravi Kumar, Patel, Reema Anil, Kim, Edward, Kalyan, Aparna, Smaglo, Brandon George, Amin, Manik A., Al Hallak, Mohammed Najeeb, Gbolahan, Olumide B., Siu, Lillian L., Moscow, Jeffrey, Spreafico, Anna

“…4136 Background: Mesothelin (MSLN) is overexpressed in 80-85% of pancreatic adenocarcinomas (PDAC). Anetumab ravtansine (AR) is a fully human anti-MSLN…”
Get full text

A phase Ib trial of anti-VEGFR/PDGFR vorolanib combined with immune checkpoint inhibitors (CPIs) in solid tumors by Bagegni, Nusayba Ali, Tan, Benjamin R., Park, Haeseong, Kraft, Katlyn, Amin, Manik A., Lim, Kian-Huat, Morgensztern, Daniel, Pedersen, Katrina, Suresh, Rama, Trikalinos, Nikolaos, Wang-Gillam, Andrea

“…Abstract only TPS472 Background: Immune CPIs have become a standard treatment option for many advanced malignancies, including gastric (G)/GE junction (GEJ)…”
Get full text

Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers by Jin, Ramon, Park, Haeseong, Wang-Gillam, Andrea, Suresh, Rama, Rigden, Caron E., Amin, Manik A., Tan, Benjamin R., Pedersen, Katrina, Lim, Kian-Huat, Trikalinos, Nikolaos, Acharya, Abhi, Copsey, Megan, Navo, Katie, Morton, Ashley, Gao, Feng, Lockhart, A. Craig

“…Abstract only 4532 Background: Standard first-line regimens for patients with metastatic gastroesophageal adenocarcinomas have moderate clinical benefit with…”
Get full text

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC) by Bendell, Johanna C., LoRusso, Patricia, Overman, Michael J., Noonan, Anne M., Kim, Dong-Wan, Strickler, John, Kim, Sang-We, Clarke, Stephen John, George, Thomas J., Grimison, Peter S., Barve, Minal A., Amin, Manik A., Desai, Jayesh, Wise-Draper, Trisha, Cooper, Zachary, Elgeioushi, Nairouz, Mueller, Nancy Kathryn, Kumar, Rakesh, Wu, Kevin YuFeng, Patel, Sandip Pravin

“…Abstract only 9047 Background: Upregulation of CD73 in multiple cancers increases adenosine production, leading to local immunosuppression. Oleclumab, a human…”
Get full text

Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma by Park, Haeseong, Trikalinos, Nikolaos, Sanjeevaiah, Aravind, Pedersen, Katrina, Bagegni, Nusayba Ali, Nixon, Andrew B., Huffman, Jesse, Tan, Benjamin R., Suresh, Rama, Lim, Kian-Huat, Amin, Manik A., Wang-Gillam, Andrea, Lockhart, A. Craig

“…Abstract only TPS4150 Background: Ramucirumab is used for treatment of metastatic gastroesophageal adenocarcinoma after disease progression on first-line…”
Get full text

A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) by Wang-Gillam, Andrea, Du, Lingling, Teague, Andrea S., Suresh, Rama, Lim, Kian-Huat, Amin, Manik A., Pedersen, Katrina, Tan, Benjamin R., Huffman, Jess, Lockhart, Albert C.

“…Abstract only 410 Background: Recent advances in front-line therapy have improved survival in patients with advanced PDAC. A fluorouracil-based regimen is…”
Get full text

Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer by Wang-Gillam, Andrea, Lockhart, Albert C., Tan, Benjamin R., Suresh, Rama, Singh, Preet Paul, Lim, Kian-Huat, Pedersen, Katrina, Amin, Manik A., Hawkins, William G., DeNardo, David G

“…Abstract only TPS505 Background: Focal adhesion kinase (FAK) is consistently hyperactivated in pancreatic ductal adenocarcinoma (PDAC), and FAK signaling is a…”
Get full text